Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.25.0.1
Commitments and Contingencies (Details Narrative)
€ in Millions
 1 Months Ended 3 Months Ended
Aug. 31, 2024
Apr. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2024
EUR (€)
Apr. 30, 2023
USD ($)
Jan. 31, 2019
USD ($)
Jul. 31, 2012
USD ($)
Discovery Collaboration Agreements [Member]                  
Loss Contingencies [Line Items]                  
License fees       $ 100,000 $ 0        
Discovery Collaboration Agreements [Member] | XOMA [Member]                  
Loss Contingencies [Line Items]                  
Milestone payments                 $ 3,800,000
Discovery Collaboration Agreements [Member] | XOMA [Member] | In Process Research and Development [Member]                  
Loss Contingencies [Line Items]                  
License fees   $ 500,000   0 0        
Cellca Agreement [Member]                  
Loss Contingencies [Line Items]                  
Milestone payments       $ 600,000          
Description of milestone payments       The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised.          
Cellca Agreement [Member] | Maximum [Member]                  
Loss Contingencies [Line Items]                  
Milestone payments               $ 700,000  
Payment for annual license fee obligation       $ 600,000          
Cellca Agreement [Member] | Minimum [Member]                  
Loss Contingencies [Line Items]                  
Payment for annual license fee obligation       100,000          
Cellca Agreement [Member] | In Process Research and Development [Member]                  
Loss Contingencies [Line Items]                  
License fees       0 0        
Commercial product license fee payment obligation   $ 100,000              
The Brink Agreement [Member]                  
Loss Contingencies [Line Items]                  
License fees       12,000,000,000 12,000,000,000        
Commercial product license fee payment obligation       100,000          
[custom:PaymentOfAnnualLicenseFeeObligation-0]             $ 12,000    
The Brink Agreement [Member] | In Process Research and Development [Member]                  
Loss Contingencies [Line Items]                  
[custom:DevelopmentLicenseFeePaymentObligation-0]       100,000          
InvivoGen Agreement [Member]                  
Loss Contingencies [Line Items]                  
License fees       0 $ 0        
Payment for annual license fee obligation       $ 100,000   € 0.1      
SOC Agreement [Member]                  
Loss Contingencies [Line Items]                  
Agreements description Company establishes a partnership with a third party prior to the initiation of the initial efficacy combination trial under this collaboration, the Company will incur, payable to the SOC, a one-time fee equal to the greater of 5% or $1.5 million from the first upfront payment received from such third party partnership                
Navigo Agreement [Member] | Navigo Proteins GmbH [Member] | Technology Service [Member]                  
Loss Contingencies [Line Items]                  
Milestone payments     $ 1,000,000.0            
Payments to Acquire in Process Research and Development     100,000            
Evaluation milestone recognized     $ 300,000